Recently, Jiangsu Provincial People’s HospitalDirector Sun Wei, Director Zhang Hao, Director Yong Yonghong, Dr. Zou Huayiyang< /strong>The NoYA™ radiofrequency atrial shunt system was successfully used to complete atrial shunt in an 81-year-old female patient with refractory heart failure. The patient recovered well after surgery. Jiangsu Provincial People’s HospitalDirector Kong Xiangqing’s teamon the NoYA™ Radiofrequency Interventricular Shunt System The application of the hospital will promote the development of the hospital’s cardiology technology and bring good news to the vast number of heart failure patients in the surrounding areas.
Patient Preoperative Evaluation > Chief Complaint: Repeated chest tightness and asthma for more than 2 months, which worsened for 3 days.
History of present illness: Patient after 2 months after repeated activity without obvious incentive Chest tightness and asthma, walking on flat ground no more than 100 meters, and resting for about half an hour can be relieved on its own. At the beginning of March, chest tightness, dizziness, and edema of both lower extremities recurred. He was admitted to our hospital. No severe stenosis was found in CAG. After symptomatic treatment, the patient was discharged. In mid-April, the patient suffered from chest tightness and asthma, and was unable to lie down, and his lower extremities were edema. After being admitted to the emergency department of our hospital, he was transferred to the Department of Cardiology, and the diagnosis was: hypertrophic cardiomyopathy, NYHA class II-III cardiac function, paroxysmal atrial fibrillation, and heart failure (NT-proBNP 18863 pg/ml). 6 minutes walking distance: 267 meters.
Preoperative AssessmentUltrasonic Prompt: LVEF 61.7%, LAD 49mm, LVDd 51mm, RAD 33mm, RVDd 30mm, IVS 25mm, LVPW 15mm. Mild calcification of the aortic valve with moderate insufficiency, moderate insufficiency of the mitral valve, moderate insufficiency of the tricuspid valve, and a small amount of pericardial effusion.
Preoperative right heart catheterization assessment: pulmonary arterial pressure 31/16 (22) mmHg, pulmonary capillary Vascular wedge pressure PCWP 16mmHg, right atrial pressure 10/4 (6) mmHg, mean pressure gradient 10mmHg, cardiac index CI 2.1L/min/m², cardiac output CO 3.2L/min.
use productproduct name:NoYA™ Radiofrequency Atrial Shunt System.
Product Model: Adjustable Atrial Shunt System: NS-IAS-0513 Radiofrequency Ablation Device:NSRF-GR.
Patient Preoperative Analysis & Surgical StrategyPreoperative Analysis: The patient is an elderly woman with hypertrophic non-obstructive cardiomyopathy, NYHA class II-III, enlarged left atrium, repeated symptoms despite adequate medication, and poor exercise tolerance. After preoperative screening and expert review, it was considered that the patient had indications for radiofrequency atrial shunt. Access options:The instrument is inserted after the right femoral vein puncture.
Surgical strategy:The procedure was performed under local anesthesia, guided by intracardiac ultrasonography (ICE), using an adjustable atrial shunt system Atrial septostomy is performed. The hole-making effect is ideal, and the instrument is completely withdrawn from the body after safe hole-making. Postoperative intracardiac ultrasonography revealed a detectable 7.1 mm atrial septal defect with left-to-right blood shunt, and the peak flow velocity of the shunt hole was 1.2 m/s. Immediately after the operation, the right heart catheter was reexamined, and the hemodynamic indexes improved significantly. Left atrial pressure dropped to 10 mmHg and right atrial pressure was 14/6 (8) mmHg. Cardiac index CI 2.9 L/min/m², cardiac output CO 4.3 L/min.
Patient surgical status
Preoperative intracardiac ultrasound
“> /img>
before electrode holder release
/span>
postoperative intracardiac ultrasound /span>
Product introductionHangzhou Nuosheng Medical Technology Co., Ltd. System”, is the world’s first self-developed non-implantable, adjustable atrial shunt product. The atrial septal tissue around the stent is heated, coagulated and contracted by radiofrequency energy to form a permanent atrial septostomy. After the operation, the system is completely withdrawn from the body without leaving any implants.
RFCroom shunt system has the following significant innovations and clinical application value:
1) Non-implantation: Complications caused by implantable products can be avoided, patients do not need to take antithrombotic drugs for a long time, and it will not affect subsequent cardiac surgery that may be required;
2) Adjustable aperture: personalized shunt aperture, perfectly adapted to the needs of patients with different hemodynamic parameters;
3) Repeatable release: easier to operate, allowing Intraoperative and postoperative multiple ablation and can meet the patient’s subsequent repeated ablation needs.
Product Images:
“300” layout=”responsive” sizes=”(min-width: 320px) 320px, 100vw” src=”https://mmbiz.qpic.cn/mmbiz_png/gNs7FU1aibQTuG2yAdf1B67MRonPuWL3ibfJxOBvU4aKKDDg12iadNEWd1dHRhoVUfyjtpib15f47hQ8EDb3ymYP4A/64im0″ width=”width=”300″ >
Professional Profile
Kong Xiangqing
Chief physician
Professor, doctor of medicine, doctoral supervisor. He is currently the director of the Department of Cardiology of the First Affiliated Hospital of Nanjing Medical University, and the secretary of the Party Committee of Suzhou Hospital Affiliated to Nanjing Medical University. He is also a member of the European Society of Cardiology (ESC), the American College of Cardiology (ACC), the American Society for Cardiovascular Angiography and Intervention (SCAI), and the Chinese Medical Association Cardiovascular He is a member of the Standing Committee of the Cardiovascular Disease Branch and the leader of the Cardiovascular Innovation and Transformation Group, the chairman of the Cardiovascular Medicine Branch of the Jiangsu Medical Association, and a member of the chairman of the Hypertension Branch of the Jiangsu Medical Association..
From 2001 to 2012, he led the team to successfully develop a symmetrical ventricular septal defect occluder and a bioceramic coating occluder, and established supporting interventional treatment technologies. The products and technologies were extended to In more than 30 countries and regions, the research results won the second prize of the 2014 National Technology Invention Award and the first prize of the 2013 Ministry of Education Science and Technology Progress Award. The “Interventional Treatment of Congenital Heart Disease” edited by him is the first monograph and classic textbook on interventional treatment of congenital heart disease in China. From 2007 to 2011, he was funded by the National 863 Program, and completed the research and development of the first domestic independent innovative interventional artificial aortic valve and pulmonary valve device and the clinical transformation of valve products. As an operator, he completed the world’s first percutaneous artificial self-expanding pulmonary artery in 2012. Valve implantation in the treatment of cases of pulmonary valve insufficiency. In 2013, it began to independently develop the world’s first non-invasive ultrasound treatment equipment for integrated diagnosis and treatment, real-time temperature measurement of hypertension, and the project was funded by the National Natural Science Foundation of China Major Scientific Instrument Project in 2016. Begin formal clinical registration. In the past five years, he has obtained 6 national invention patents and published 76 scientific research papers, including 57 SCI papers by the first and corresponding author. He has accumulated rich experience in interdisciplinary collaboration and achievement transformation, and has formed an effective collaborative innovation mechanism.
Sun Wei
Chief Physician
Associate Professor, MD span>、Master tutor. He is currently the deputy director of the Hypertension Branch of the Jiangsu Medical Association, a young member of the Cardiovascular Branch of the Chinese Medical Association, a member of the Hypertension Professional Committee of the Jiangsu Medical Association, a young member of the Hypertension Professional Committee of the Chinese Medical Association, and the Cardiovascular Medicine Branch of the Chinese Medical Association. Member of Metabolic Cardiology Group, director of Jiangsu Anzhong Medical Service and Health Management Research Institute. He is good at drugs and interventional therapy for hypertension, structural heart disease and heart failure, and presided over 1 national key research and development project; 2 second prizes; 1 first prize of Jiangsu Provincial Health Department New Technology Introduction Award; 1 second prize of Nanjing Science and Technology Progress Award. In the past five years, he has published 36 SCI papers as the first author and corresponding author. 3 invention patents and 6 utility model patents have been granted.